Research programme: fibrotic diseases diagnostic agents - Sunbird Bio
Latest Information Update: 28 Feb 2025
At a glance
- Originator Glympse Bio
- Developer Sunbird Bio
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Fibrosis(Diagnosis) in USA
- 31 Mar 2021 Fibrotic diseases diagnostic agents - Glympse Bio is available for licensing as of 31 Mar 2021. https://glympsebio.com/collaborators/
- 21 Jan 2021 Preclinical trials in Fibrosis (Diagnosis) in USA (unspecified route) before January 2021 (Glympse Bio pipeline, January 2021)